Pancreatic Cancer Research

ResearcherKumamoto Regional Medical CenterActive in the last 2 years

Hirohisa Okabe

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4943-4523; OpenAlex author ID A5103015228. Sources: OpenAlex.

Their work

Papers
24 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
54
Papers, trials and grants by year

2015: 1 paper · 2016: 2 papers · 2017: none · 2018: 3 papers · 2019: 2 papers · 2020: 1 paper · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: 2 papers · 2025: none · 2026: 10 papers

Papers 24

  1. Outcomes of Resected Cases of Pancreatic Ductal Adenocarcinoma Patients With Unexpected Postoperative Uncovering Noncurative Factors: A Multicenter Retrospecti… Co-author DOI 10.1002/ags3.70090↗
  2. Preoperative Total Iron-Binding Capacity Is a Potential Surrogate Marker of Long-Term Outcomes After Pancreatectomy for Pancreatic Cancer. Co-author DOI 10.1002/ags3.70297↗
  3. High γ-H2AX Predicts Clinical Benefit From Platinum-Based Chemotherapy (mFOLFIRINOX) at Recurrence After Pancreatic Cancer Resection. Co-author DOI 10.1002/jhbp.70032↗
  4. A case of pancreatic cancer with high microsatellite instability exhibiting rare clinical features. First author DOI 10.1007/s12328-025-02256-2↗
  5. A case of long-term survival in unresectable pancreatic cancer with BRCA germline mutation treated with platinum-based chemotherapy. Co-author DOI 10.1007/s12328-026-02359-4↗
  6. The clinical utility of nutritional and immunological indices as prognostic factors in pancreatic cancer after pancreatectomy. Co-author DOI 10.1016/j.pan.2026.04.008↗
  7. Neoadjuvant Chemotherapy Diminishes Ki-67 Overexpression and Persistent Overexpression Is a Poor Prognostic Factor in Pancreatic Ductal Adenocarcinoma After Pa… Co-author DOI 10.1097/mpa.0000000000002641↗
  8. Evaluation of Claudin 18.2 Expression Changes Following Chemotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/anticanres.18442↗
  9. An 8-Year Survivor after Three-Time Hepatectomies for Metachronous Pancreatic Adenocarcinoma Liver Metastases. First author DOI 10.70352/scrj.cr.25-0242↗
  10. A Case of Pancreatic Cancer with High Tumor Mutation Burden Showing a Remarkable Response to Pembrolizumab. Co-author DOI 10.70352/scrj.cr.26-0273↗
  11. Impairment of perioperative activities of daily living is associated with poor prognosis following pancreatectomy for pancreatic cancer. Co-author DOI 10.1007/s00423-024-03478-7↗
  12. Combined Neutrophil-to-Lymphocyte Ratio Score Is Associated With Chemotherapeutic Response and Predicts Prognosis in Patients With Advanced Pancreatic Cancer. Co-author DOI 10.21873/anticanres.16955↗
  13. Preoperative serum CA19-9 predicts postoperative pancreatic fistula in PDAC patients: retrospective analysis at a single institution. First author DOI 10.1186/s12893-022-01825-3↗
  14. Prognostic Value of the Preoperative Tumor Marker Index in Resected Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Institution Study. Co-author DOI 10.1245/s10434-020-09022-3↗
  15. High ARHGEF2 (GEF-H1) Expression is Associated with Poor Prognosis Via Cell Cycle Regulation in Patients with Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-09383-9↗
  16. Efficacy of Staging Laparoscopy for Pancreatic Cancer. Co-author DOI 10.21873/anticanres.14037↗
  17. PD-L1 expression enhancement by infiltrating macrophage-derived tumor necrosis factor-α leads to poor pancreatic cancer prognosis. Co-author DOI 10.1111/cas.13874↗
  18. Cellular Senescence, Represented by Expression of Caveolin-1, in Cancer-Associated Fibroblasts Promotes Tumor Invasion in Pancreatic Cancer. Co-author DOI 10.1245/s10434-019-07266-2↗
  19. Clinical usefulness of postoperative C-reactive protein/albumin ratio in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.amjsurg.2017.08.016↗
  20. Downregulation of 15-hydroxyprostaglandin dehydrogenase by interleukin-1β from activated macrophages leads to poor prognosis in pancreatic cancer. Co-author DOI 10.1111/cas.13467↗
  21. Cystic gastric metastasis from pancreatic cancer. Co-author DOI 10.1186/s40792-018-0443-2↗
  22. Intraoperative blood loss is not a predictor of prognosis for pancreatic cancer. Co-author DOI 10.1007/s00595-015-1238-8↗
  23. The diagnostic role of the neutrophil-to-lymphocyte ratio in predicting pancreatic ductal adenocarcinoma in patients with pancreatic diseases. First author DOI 10.1007/s10147-016-0975-z↗
  24. Significance of P-cadherin overexpression and possible mechanism of its regulation in intrahepatic cholangiocarcinoma and pancreatic cancer. Co-author DOI 10.1111/cas.12732↗

Closest collaborators

The 25 strongest of 54 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiromitsu Hayashi · 15 shared papers, 2015–2026 · strength 3.09
  2. Yuki Kitano · 13 shared papers, 2016–2026 · strength 2.60
  3. Masaaki Iwatsuki · 8 shared papers, 2026 · strength 2.24
  4. Shigeki Nakagawa · 12 shared papers, 2015–2026 · strength 1.84
  5. Takanobu Yamao · 9 shared papers, 2018–2026 · strength 1.38
  6. Shinsei Yumoto · 5 shared papers, 2026 · strength 1.36
  7. Rumi Itoyama · 7 shared papers, 2018–2026 · strength 1.33
  8. Tatsunori Miyata · 8 shared papers, 2018–2026 · strength 1.11
  9. Toru Takematsu · 3 shared papers, 2026 · strength 0.84
  10. Masahiko Hirota · 4 shared papers, 2019–2026 · strength 0.74
  11. Yuki Adachi · 3 shared papers, 2024–2026 · strength 0.74
  12. Hideo Baba · 8 shared papers, 2015–2024 · strength 0.70
  13. Hiroki Sugita · 3 shared papers, 2022–2026 · strength 0.67
  14. Naoki Umezaki · 5 shared papers, 2018–2026 · strength 0.63
  15. Katsunori Imai · 8 shared papers, 2015–2021 · strength 0.63
  16. Takashi Matsumoto · 2 shared papers, 2026 · strength 0.57
  17. Akira Chikamoto · 8 shared papers, 2015–2021 · strength 0.55
  18. Toshiro Masuda · 2 shared papers, 2024–2026 · strength 0.50
  19. Hidetoshi Nitta · 4 shared papers, 2015–2026 · strength 0.50
  20. Takashi Ofuchi · 2 shared papers, 2024–2026 · strength 0.50
  21. Masayo Tsukamoto · 6 shared papers, 2018–2021 · strength 0.49
  22. Kosuke Mima · 2 shared papers, 2024–2026 · strength 0.49
  23. Kota Arima · 7 shared papers, 2016–2020 · strength 0.49
  24. Daisuke Hashimoto · 6 shared papers, 2016–2020 · strength 0.41
  25. Kensuke Yamamura · 5 shared papers, 2016–2020 · strength 0.38

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.